Stephanie Léouzon

Stephanie Léouzon

Partner and Head of Torreya Europe

London Office  |   |   +44 (0) 207 451 4551

Stephanie Léouzon is Partner and Head of Torreya Europe. She has worked on over 100 strategic and financing transactions in the biopharmaceutical industry, with an aggregate value of over $75 billion.

Stephanie joined Torreya in 2011. Previously, she was a Managing Director and Senior Advisor at Credit Suisse in London. She has also worked at Salomon Brothers, as a Director of Healthcare Investment Banking, and as a Vice President in the Investment Banking divisions of JP Morgan, and Lehman Brothers in New York.

Highlights of Stephanie’s strategic advisory experience include the $34.6 billion Astra and Zeneca merger, the $6.8 billion Pharmacia & Upjohn merger, Hoechst’s $7 billion acquisition of Marion Merrell Dow; the creation of Syngenta through the merger of the agricultural businesses of AstraZeneca and Novartis; and the $3.1 billion Warner Chilcott LBO.

She has also led financings across several life sciences sectors, focusing on biotechnology and specialty pharma. She has worked on more than 15 Initial Public Offerings (IPOs) including Movetis, Warner Chilcott, Syngenta, GPC Biotech, Ark Therapeutics, Walsh International, IDEXX Labs, Viropharma, Pharmaceutical Marketing Services Inc., and Geron Corp. She has led Secondaries, Convertibles, Private Placements for, among many others, National Health Laboratories, Marion Merrell Dow, Oxford Glycosciences, BTG Therapeutics, Gilead Sciences, Skye Pharma, Centocor, Ark Therapeutics, American Medical Response, Pharmaceutical Marketing Services, Virco Holdings, and NaPro Biotherapeutics. A notable debt financing was the $2.4 billion bank and high yield financings for the LBO of Warner Chilcott.

Stephanie earned a B.A. cum laude from Mount Holyoke College and an M.A. and an M.B.A. from the Darden School at the University of Virginia.

She currently serves as a Non-Executive Director on the Board of BioPharma Credit PLC and also as a member of the Advisory Board for Great Ormond Street Hospital's Digital Research, Informatics and Virtual Environments (DRIVE) unit.

Selected Transactions

Midatech Pharma PLC
Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC
Up to $19 million
November 2018
Licensing of ex European rights for LYS-SAF302 to
Sarepta Therapeutics
Up to $125 Millionwith committed payments of $29m plus royalties
October 2018
Shield Therapeutics
Licensing agreement for Feraccru® in Europe, Australia and New Zealand with
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
September 2018
Company sale to
> €75 million
November 2016
DBV Technologies
License of
milk allergy product to
€100 million
May 2016
Equity Financing Round
€44.5 million
October 2020
Mereo Biopharma
License of
Navicixizumab to
Up to $306 million
January 2020
License of Feraccru® in China to
Beijing Aosaikang Pharmaceutical
$62.8 million
January 2020
Sale of two orphan drug programs to
Rally Bio
August 2019
License of Nefecon in Greater China and Singapore to
Up to $121 million
June 2019
Midatech Pharma
Acquisition of
Dara Biosciences
Up to $30 million
December 2015
Acquisition of
OctreoPharm Sciences
Up to €50 million
May 2015
Financial advisor
on IPO
$30 million
October 2014
DBV Technologies
Global offering advisory
$133 million
October 2014
DBV Technologies
Financial advisor in
private placement
€29.9 million
November 2013
Sale of
vaccine company to
$250 million with
$35 million upfront
May 2013
Collaboration with
December 2012